Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA306517 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:DNA-methylation profiling of Whole blood genomic DNAs collected at EDIC baseline and monocytes at EDIC years 16/17 years from participants of Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study This SuperSeries is composed of the SubSeries listed below.
2016-05-15 | GSE76171 | GEO
Project description:DNA-methylation profiling of Whole blood genomic DNAs collected at EDIC baseline and monocytes at EDIC years 16/17 years from participants of Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
2016-05-15 | E-GEOD-76171 | biostudies-arrayexpress
Project description:DNA-methylation profiling of monocyte genomic DNAs collected from participants of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study
| PRJNA306516 | ENA
Project description:Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications Study (EDIC)
| PRJNA75635 | ENA
Project description:Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications Study (EDIC)
| PRJNA75633 | ENA
Project description:<p>The Diabetes Control and Complications Trial (DCCT, 1982-93) and the Epidemiology of Diabetes Interventions and Complications follow-up study (EDIC, 1994-2016) have been ongoing for more than twenty years. After a mean follow-up of approximately 16 years, the DCCT-EDIC cohort of 1,441 Type 1 diabetics had remained remarkably complete with more than 90% of the original cohort being actively followed. Taken together, the DCCT clinical trial and subsequent EDIC longitudinal follow-up provide a uniquely rich source of information on the impact of intensive therapy on glycemia and the its long-term complications for persons with Type 1 diabetes.</p> <p>The DCCT was a multicenter, randomized clinical trial (1, 2) designed to compare intensive with conventional diabetes therapy with regard to their effects on the development and progression of the early complications of Type 1 diabetes. The DCCT trial found that "intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy" in patients with Type 1 diabetes (1). The goal of the EDIC follow-up was to examine the longer term effects of the original DCCT interventions, especially as they apply to late-occurring complications, such as cardiovascular disease and more advanced stages of retinal and renal disease (3). The EDIC study has been remarkably fruitful in discovering the long term "imprinting" effects (metabolic memory) of the previous intensive therapy, and in delineating the interactions among risk factors with regard to microvascular complications (4-6). In addition, EDIC established, for the first time, the role of intensive therapy and chronic glycemia on atherosclerosis (7-9). </p> <p><b>Note:</b> This study description has been prepared using materials authored by the DCCT-EDIC Data Coordinating Center.</p> <p><a href="GetPdf.cgi?id=phd000390" target="_blank">DETAILED DESCRIPTION OF STUDY</a></p>
| phs000086 | dbGaP
Project description:<p>The Diabetes Control and Complications Trial (DCCT, 1982-93) and the Epidemiology of Diabetes Interventions and Complications
follow-up study (EDIC, 1994-2016) have been ongoing for more than twenty years. After a mean follow-up of approximately 16 years,
the DCCT-EDIC cohort of 1,441 Type 1 diabetics had remained remarkably complete with more than 90% of the original cohort being
actively followed. Taken together, the DCCT clinical trial and subsequent EDIC longitudinal follow-up provide a uniquely rich source
of information on the impact of intensive therapy on glycemia and the its long-term complications for persons with Type 1 diabetes.
</p>
<p>The DCCT was a multicenter, randomized clinical trial (1, 2) designed to compare intensive with conventional diabetes therapy with regard
to their effects on the development and progression of the early complications of Type 1 diabetes. The DCCT trial found that "intensive
therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy" in patients with Type
1 diabetes (1). The goal of the EDIC follow-up was to examine the longer term effects of the original DCCT interventions, especially as
they apply to late-occurring complications, such as cardiovascular disease and more advanced stages of retinal and renal disease (3).
The EDIC study has been remarkably fruitful in discovering the long term "imprinting" effects (metabolic memory) of the previous intensive
therapy, and in delineating the interactions among risk factors with regard to microvascular complications (4-6). In addition, EDIC
established, for the first time, the role of intensive therapy and chronic glycemia on atherosclerosis (7-9).
</p>
<p><b>Note:</b> This study description has been prepared using materials authored by the DCCT-EDIC Data Coordinating Center.</p>
<p><a href="GetPdf.cgi?id=phd000390" target="_blank">DETAILED DESCRIPTION OF STUDY</a></p>
| phs000086.v2.p1 | EGA
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Ac at 22K gene promoters in peripheral blood monocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study.
2013-12-31 | GSE47384 | GEO
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K4Me3 at 22K gene promoters in peripheral blood monocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study.
2013-12-31 | GSE47383 | GEO
Project description:Chromatin immunoprecipitation linked to tiling arrays (ChIP-chip) were performed to profile histone H3K9Me2 at 22K gene promoters in peripheral blood lymphocytes obtained in 2009-10 from 60 selected DCCT participants being followed in the long-term observational EDIC study.
2013-12-31 | GSE47382 | GEO